Objective: To observe the therapeutic effect of Xuesaitong soft capsule(血塞通软胶囊, XST)and its effect on platelet counts, coagulation factor 1 (CF1) as well as hemorrheologic indexes in treating patients with acute...Objective: To observe the therapeutic effect of Xuesaitong soft capsule(血塞通软胶囊, XST)and its effect on platelet counts, coagulation factor 1 (CF1) as well as hemorrheologic indexes in treating patients with acute cerebral infarction (ACI). Methods: Two hundred and four patients with ACI were assigned into two groups, the control group (n=96) and the treated group (n=108). They were all treated with conventional Western medicines, including mannitol, troxerutin, citicoline, piracetam and aspirin, while to the treated group, XST was given additionally through oral intake, twice a day, 2 capsules each time for 8 successive weeks. The clinical efficacy was evaluated according to the nerve function deficits scoring and the changes of platelet count. CF1 and hemorrheological indexes were measured before and after treatment.Results: The total effective rate was 87.0% in the treated group, and 87.5% in the control group, respectively, showing insignificant difference between them. But the markedly effective rate in the treated group ( 66.7%) was significantly higher than that in the control group (27.1%, P<0.01). The count of platelet was not changed significantly in both groups after treatment, while CF1 in them evidently lowered at the end of the 4th and 8th weeks of treatment, but showed insignificant difference between the two groups. The hematocrit, whole blood viscosity and plasma viscosity in both groups were all improved significantly after treatment, but also showed insignificant difference in comparison of the two groups. Conclusion: XST has good efficacy in auxiliary treatment of patients with ACI, though its mechanism remains to be further explored.展开更多
Objective: To study the effect of Xuesaitong soft capsule (血塞通软胶囊, XST) on liver fibrosis criteria in patients with post-hepatitis fibrosis. Methods: Sixty-four patients with such fibrosis were randomly divided ...Objective: To study the effect of Xuesaitong soft capsule (血塞通软胶囊, XST) on liver fibrosis criteria in patients with post-hepatitis fibrosis. Methods: Sixty-four patients with such fibrosis were randomly divided into the treated group and control group. They were treated with XST and Dahuang Zhechong pill (大黄NFDA1虫丸) for 3 months respectively. Their liver fibrosis criteria were examined before and after treatment. Results: The levels of serum procollagen Ⅲ, hyaluronic acid, collagen Ⅳ, laminin in the two groups were significantly lower ( P <0.01) than those before treatment. The differences between the two groups were insignificant ( P >0.05). Conclusion: XST could recover liver dysfunction and had anti-liver fibrosis function.展开更多
Objective: To observe the effect of Xuesaitong (血塞通, XST) soft capsule in interference treatment on patients of nephrosis syndrome (NS) during corticosteroid (CS) dose reducing stage. Methods: Seventy-one NS patien...Objective: To observe the effect of Xuesaitong (血塞通, XST) soft capsule in interference treatment on patients of nephrosis syndrome (NS) during corticosteroid (CS) dose reducing stage. Methods: Seventy-one NS patients applying prednisone and initiating dose reducing stage were randomized into trial group and control group. On the basis of conventional prednisone dose reduction of both groups, the trial group was given additionally XST, and the treatment course ended with the reduction to maintenance dose. In the course of observation, those who did not comply with the criteria of observation were excluded. Before and after the dose reduction, TCM syndrome scoring, 24 hrs urinary protein amount, blood β2-microglobulin (β2-MG), urinary β2-MG, blood fibrinogen (Fbg), plasma prothrombin time (PT), blood lipid, etc. were observed. Results: The trial group of XST could obviously lower their urinary protein amount and blood lipid level (P<0.05 or P<0.01), markedly improve the blood coagulation parameters (P<0.01), improve the TCM syndrome and CS induced adverse reaction (P<0.05 or P<0.01), also obviously reduced the recurrence rate of NS (P<0.05). Conclusion: XST could obviously improve the clinical symptoms and renal impairment parameters in NS patients during CS dose reduction stage, improve the CS induced adverse reaction and prevent the recurrence of NS.展开更多
Objective:To obtain a formulation with high bioavailability through evaluation of the stability of three types of Xuesaitong capsules in the stomachs and intestines of rats.We compared the stability of the Panax notog...Objective:To obtain a formulation with high bioavailability through evaluation of the stability of three types of Xuesaitong capsules in the stomachs and intestines of rats.We compared the stability of the Panax notoginsenoside R1 as well as the ginsenosides Rg1,Rb1,Re,and Rd in different formulations.Methods:Artificial stomach fluid(ASF)and artificial intestinal fluid(AIF)were prepared.Stability of three types of Xuesaitong capsules was examined for 4 h in stomachs and 24 h in intestines.Samples were analyzed at different times by high-performance liquid chromatography.Percent content of NGR1,GRg1,GRb1,GRe,and GRd at different times was calculated.Results:Hard capsules incubated in ASF disintegrated within 2e3 min,whereas soft capsules disintegrated within 7e8 min.Components in hard capsules were dissolved rapidly in water,with content of each compound reaching 90%in 5 min,and degradation of each compound reaching 30e50%after incubation for 240 min.Dissolution and degradation of each component in soft capsules with a water-soluble base tended to balance at 30 e90 min.Contents in soft capsules with a lipid-soluble base showed slow dissolution after ASF incubation for 120 min.Five saponins in identical types of capsules incubated in ASF had similar stability curves.Contents of hard capsules and soft capsules with a watersoluble base degraded rapidly within 30 min and reached a plateau when Xuesaitong capsules were incubated in AIF.展开更多
目的:基于中国卫生服务体系角度评价血塞通软胶囊对比安慰剂治疗缺血性中风患者的经济性。方法:基于血塞通软胶囊的Ⅲ期对照试验和已发表的文献数据构建markov模型,模拟患者终身的质量调整生命年(quality-adjusted life year,QALY)和增...目的:基于中国卫生服务体系角度评价血塞通软胶囊对比安慰剂治疗缺血性中风患者的经济性。方法:基于血塞通软胶囊的Ⅲ期对照试验和已发表的文献数据构建markov模型,模拟患者终身的质量调整生命年(quality-adjusted life year,QALY)和增量成本效果比(Incremental cost-effectiveness ratio ICER),并进行单因素敏感性分析和概率敏感性分析检验模型的不确定性。结果:基础分析结果显示,与安慰剂组相比,血塞通软胶囊在获得0.32个QALY且节约医疗成本,具有绝对优势,单因素敏感性分析和概率敏感性分析验证了模型的稳健性。单因素敏感性分析显示对模型结果影响程度最大的4个因素分别是mRS3-5首次住院成本、mRS0-2首次住院成本、mRS0-2的状态效用值及贴现率;概率敏感性分析显示在我国的意愿支付值之下血塞通软胶囊具有经济性的概率为100%。结论:与安慰剂相比,血塞通软胶囊在提升QALY的同时降低了相应的成本,对治疗我国缺血性中风患者具有经济性。展开更多
文摘Objective: To observe the therapeutic effect of Xuesaitong soft capsule(血塞通软胶囊, XST)and its effect on platelet counts, coagulation factor 1 (CF1) as well as hemorrheologic indexes in treating patients with acute cerebral infarction (ACI). Methods: Two hundred and four patients with ACI were assigned into two groups, the control group (n=96) and the treated group (n=108). They were all treated with conventional Western medicines, including mannitol, troxerutin, citicoline, piracetam and aspirin, while to the treated group, XST was given additionally through oral intake, twice a day, 2 capsules each time for 8 successive weeks. The clinical efficacy was evaluated according to the nerve function deficits scoring and the changes of platelet count. CF1 and hemorrheological indexes were measured before and after treatment.Results: The total effective rate was 87.0% in the treated group, and 87.5% in the control group, respectively, showing insignificant difference between them. But the markedly effective rate in the treated group ( 66.7%) was significantly higher than that in the control group (27.1%, P<0.01). The count of platelet was not changed significantly in both groups after treatment, while CF1 in them evidently lowered at the end of the 4th and 8th weeks of treatment, but showed insignificant difference between the two groups. The hematocrit, whole blood viscosity and plasma viscosity in both groups were all improved significantly after treatment, but also showed insignificant difference in comparison of the two groups. Conclusion: XST has good efficacy in auxiliary treatment of patients with ACI, though its mechanism remains to be further explored.
文摘Objective: To study the effect of Xuesaitong soft capsule (血塞通软胶囊, XST) on liver fibrosis criteria in patients with post-hepatitis fibrosis. Methods: Sixty-four patients with such fibrosis were randomly divided into the treated group and control group. They were treated with XST and Dahuang Zhechong pill (大黄NFDA1虫丸) for 3 months respectively. Their liver fibrosis criteria were examined before and after treatment. Results: The levels of serum procollagen Ⅲ, hyaluronic acid, collagen Ⅳ, laminin in the two groups were significantly lower ( P <0.01) than those before treatment. The differences between the two groups were insignificant ( P >0.05). Conclusion: XST could recover liver dysfunction and had anti-liver fibrosis function.
文摘Objective: To observe the effect of Xuesaitong (血塞通, XST) soft capsule in interference treatment on patients of nephrosis syndrome (NS) during corticosteroid (CS) dose reducing stage. Methods: Seventy-one NS patients applying prednisone and initiating dose reducing stage were randomized into trial group and control group. On the basis of conventional prednisone dose reduction of both groups, the trial group was given additionally XST, and the treatment course ended with the reduction to maintenance dose. In the course of observation, those who did not comply with the criteria of observation were excluded. Before and after the dose reduction, TCM syndrome scoring, 24 hrs urinary protein amount, blood β2-microglobulin (β2-MG), urinary β2-MG, blood fibrinogen (Fbg), plasma prothrombin time (PT), blood lipid, etc. were observed. Results: The trial group of XST could obviously lower their urinary protein amount and blood lipid level (P<0.05 or P<0.01), markedly improve the blood coagulation parameters (P<0.01), improve the TCM syndrome and CS induced adverse reaction (P<0.05 or P<0.01), also obviously reduced the recurrence rate of NS (P<0.05). Conclusion: XST could obviously improve the clinical symptoms and renal impairment parameters in NS patients during CS dose reduction stage, improve the CS induced adverse reaction and prevent the recurrence of NS.
文摘Objective:To obtain a formulation with high bioavailability through evaluation of the stability of three types of Xuesaitong capsules in the stomachs and intestines of rats.We compared the stability of the Panax notoginsenoside R1 as well as the ginsenosides Rg1,Rb1,Re,and Rd in different formulations.Methods:Artificial stomach fluid(ASF)and artificial intestinal fluid(AIF)were prepared.Stability of three types of Xuesaitong capsules was examined for 4 h in stomachs and 24 h in intestines.Samples were analyzed at different times by high-performance liquid chromatography.Percent content of NGR1,GRg1,GRb1,GRe,and GRd at different times was calculated.Results:Hard capsules incubated in ASF disintegrated within 2e3 min,whereas soft capsules disintegrated within 7e8 min.Components in hard capsules were dissolved rapidly in water,with content of each compound reaching 90%in 5 min,and degradation of each compound reaching 30e50%after incubation for 240 min.Dissolution and degradation of each component in soft capsules with a water-soluble base tended to balance at 30 e90 min.Contents in soft capsules with a lipid-soluble base showed slow dissolution after ASF incubation for 120 min.Five saponins in identical types of capsules incubated in ASF had similar stability curves.Contents of hard capsules and soft capsules with a watersoluble base degraded rapidly within 30 min and reached a plateau when Xuesaitong capsules were incubated in AIF.
文摘目的:基于中国卫生服务体系角度评价血塞通软胶囊对比安慰剂治疗缺血性中风患者的经济性。方法:基于血塞通软胶囊的Ⅲ期对照试验和已发表的文献数据构建markov模型,模拟患者终身的质量调整生命年(quality-adjusted life year,QALY)和增量成本效果比(Incremental cost-effectiveness ratio ICER),并进行单因素敏感性分析和概率敏感性分析检验模型的不确定性。结果:基础分析结果显示,与安慰剂组相比,血塞通软胶囊在获得0.32个QALY且节约医疗成本,具有绝对优势,单因素敏感性分析和概率敏感性分析验证了模型的稳健性。单因素敏感性分析显示对模型结果影响程度最大的4个因素分别是mRS3-5首次住院成本、mRS0-2首次住院成本、mRS0-2的状态效用值及贴现率;概率敏感性分析显示在我国的意愿支付值之下血塞通软胶囊具有经济性的概率为100%。结论:与安慰剂相比,血塞通软胶囊在提升QALY的同时降低了相应的成本,对治疗我国缺血性中风患者具有经济性。
